"Canada Pharmaceuticals & Healthcare Report Q4 2010" now available at Fast Market Research

Oct. 2, 2010 - PRLog -- In BMI's Business Environment Ratings (BERs) for Q410, Canada remains in second place in the expanded regional matrix, trailing the US by around eight points. Globally, Canada ranks third of the 83 markets surveyed, after the US and now behind Australia. Despite a tightening cost-containment environment, provincial variations regarding drug approvals and subsidies and the country's appearance on the Priority Watch List in the 2010 submission of Special 301 report, Canada will remain one of the most attractive pharmaceutical markets on a worldwide scale, in part due to its high per-capita spending on medicines, which topped US$629 in 2009, as well as population expansion and ageing.

Having been valued at CAD24.2bn (US$21.2bn) at consumer prices in 2009 and accounting for around 12% of the country's GDP, the Canadian pharmaceutical market is forecast to post a compound annual growth rate (CAGR) of 4.34% in local currency terms, reaching CAD29.9bn (US$26.0bn) in value by 2014. Growth over the 2009-2019 period will slow to 3.09%, although in the latter parts of the forecast the patented medicines segment should be boosted by the use of more personalised therapies and novel medicines. Generics, however, will post the strongest five- and ten-year CAGRs, at 8.34% and 6.12% in local currency terms, respectively, to reach CAD14.9bn (US$13.0bn) in 2019 values.

However, Canada's healthcare system is facing serious challenges in terms of affordability and accessibility, as well as failing to meet the medical needs of Canada's changing demographics, according to a report released by the Canadian Medical Association (CMA) in August 2010. The country's healthcare system is increasingly being recognised as inadequate for the long-term needs of the population, and extensive reforms are being proposed ahead of the renegotiation of the current Health Accord, which is set to expire on March 31 2014. First Ministers have described the current level of spending on prescription drugs in the National Pharmaceutical Strategy as 'catastrophic', which is expected to lead to some policy changes and further cost-containment initiatives. To this end, the British Columbia government recently announced that the prices of generic drugs covered by PharmaCare are to be reduced to 35% of the price of their branded counterparts.

Market growth opportunities for the out-of-pocket segment will, however, remain limited, given the outlook for a modest growth in private consumption levels and the anticipated slowdown in GDP growth over the medium term. Despite having one of the strongest fiscal positions in the developed world, austerity has become the watchword across Canada, with Ottawa and the provinces cutting back spending. In line with a trend that is beginning to prevail across the developed world, Canadian Finance Minister Jim Flaherty reiterated during the G20 meetings in Toronto in June 2010 that the government remains set on eliminating the deficit by 2014 'or so'. In the meantime, as the Canadian consumer has proven extraordinarily resilient despite external headwinds emanating from the United States, we recently upgraded our 2010 real GDP growth forecast for 2010 from 3.1% to 3.3%, though we are still pencilling in a slowdown in 2011 to 2.4%, in line with our global outlook.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/87012_canada_pharmaceuticals_h...

Partial Table of Contents:

Executive Summary
SWOT Analysis
- Canada Pharmaceuticals And Healthcare Industry SWOT
- Canada Political SWOT
- Canada Economic SWOT
Pharmaceutical Business Environment Ratings
- Table: Americas - Pharmaceuticals Business Environment Ratings, Q410
- Rewards
- Risks
Canada - Market Summary
- Pharmacovigilance
- Biosimilars
- OTC Medicines
- Intellectual Property Regime
- International Collaboration
- Pricing Regime
- Provincial Pricing Systems
- Reimbursement Regime
- Recent Pricing and Reimbursement Developments
Industry Developments
- Epidemiology
- Healthcare Sector
- International Comparison
- Health Expenditure
- Table: Sustainability Of Public Health Expenditure And Pharmaceutical Approval Indicators
- National Pharmaceuticals Strategy
- Pharmaceutical Retail
- Research and Development Sector
- Biotechnology
- Medical Devices Industry
- Recent Developments in the Medical Devices Industry
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: Canada - Economic Activity
- Prescription Drug Market Forecast
- Patented Product Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Medical Device Market Forecast
- Pharmaceutical Trade Forecasts
- Other Healthcare Data
Competitive Landscape
- Pharmaceutical Industry
- Pharmaceutical Re-import Policy
- Recent Pharmaceutical Company Developments
Company Profiles
- Indigenous Manufacturers
- Apotex
- Biovail (Valeant)
- Leading Multinational Manufacturers
- Pfizer
- GlaxoSmithKline
- Sanofi-Aventis
- Merck and Co
- Novartis
Country Snapshot: Canada Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2000-2003
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Manufacturing Wages, 2000-2012
BMI Methodology

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=8701...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.